BioNotebook: Ambit, Xencor, Soligenix, Ampio
This article was originally published in Scrip
Executive Summary
Ambit stock drops on no accelerated filing for quizartinib; Xencor prices IPO, rises in first day; Soligenix starts Phase II orBec study; and Ampio updates Phase III Ampion status.
You may also be interested in...
Novartis Deal Gives Xencor $150m Up Front, Up To $2.41bn In Milestone Fees
Monrovia, California-based Xencor Inc.'s latest collaboration, which is worth $150m up front and up to $2.41bn in milestone fees from Novartis AG, shows how the company is growing up as its research and development pipeline matures.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.